Nadeem Rais Explains: A Clinical Comparison of AntiPlatelets vs AntiCoagulants
Nadeem Rais, Clinical Pharmacist at NMC Healthcare, shared a post on LinkedIn:
“AntiPlatelets vs AntiCoagulants
Blood clot prevention is not one-size-fits-all. Two major drug classes act at different stages of thrombosis.
• 𝗔𝗻𝘁𝗶𝗣𝗹𝗮𝘁𝗲𝗹𝗲𝘁𝘀
Drugs that inhibit platelet activation and aggregation.
𝙈𝙚𝙘𝙝𝙖𝙣𝙞𝙨𝙢 𝙊𝙛 𝘼𝙘𝙩𝙞𝙤𝙣: They block platelet-to-platelet interaction at sites of vascular injury.
𝘾𝙤𝙢𝙢𝙤𝙣 𝘿𝙧𝙪𝙜𝙨:
▪ Aspirin (Acetylsalicylic Acid)
▪ Clopidogrel (Adenosine Diphosphate Receptor Inhibitor)
▪ Prasugrel (P2Y12 Receptor Inhibitor)
▪ Ticagrelor (Reversible P2Y12 Inhibitor)
𝙈𝙖𝙟𝙤𝙧 𝙄𝙣𝙙𝙞𝙘𝙖𝙩𝙞𝙤𝙣𝙨:
▪ Myocardial Infarction (Heart Attack)
▪ Ischemic Stroke
▪ Post Percutaneous Coronary Intervention (PCI)
𝙏𝙝𝙧𝙤𝙢𝙗𝙪𝙨 𝙏𝙮𝙥𝙚: Platelet-rich clots. Also called white clots.
𝙈𝙤𝙣𝙞𝙩𝙤𝙧𝙞𝙣𝙜: Routine laboratory monitoring is usually not required.
• 𝗔𝗻𝘁𝗶𝗖𝗼𝗮𝗴𝘂𝗹𝗮𝗻𝘁𝘀
Drugs that inhibit clotting factors in the coagulation cascade.
𝙈𝙚𝙘𝙝𝙖𝙣𝙞𝙨𝙢 𝙊𝙛 𝘼𝙘𝙩𝙞𝙤𝙣: They slow or stop fibrin formation.
𝘾𝙤𝙢𝙢𝙤𝙣 𝘿𝙧𝙪𝙜𝙨:
▪ Heparin (Indirect Thrombin Inhibitor)
▪ Warfarin (Vitamin K Antagonist)
▪ Dabigatran (Direct Thrombin Inhibitor)
▪ Rivaroxaban (Factor Xa Inhibitor)
▪ Apixaban (Factor Xa Inhibitor)
𝙈𝙖𝙟𝙤𝙧 𝙄𝙣𝙙𝙞𝙘𝙖𝙩𝙞𝙤𝙣𝙨:
▪ Deep Vein Thrombosis (DVT)
▪ Pulmonary Embolism (PE)
▪ Atrial Fibrillation (AF)
𝙏𝙝𝙧𝙤𝙢𝙗𝙪𝙨 𝙏𝙮𝙥𝙚: Fibrin-rich clots. Also called red clots.
𝙈𝙤𝙣𝙞𝙩𝙤𝙧𝙞𝙣𝙜:
▪ Warfarin requires International Normalized Ratio (INR) monitoring
▪ Direct Oral Anticoagulants usually do not require routine monitoring
𝗞𝗲𝘆 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗗𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝗰𝗲
→ AntiPlatelets act early at platelet level
→ AntiCoagulants act later at coagulation factor level
Credit: Federation of Clinical Pharmacists in India (FCPI)
Repost to share with your peers
Follow Nadeem Rais, PhD for more”
Follow the latest in Hemostasis Today.
-
Apr 6, 2026, 16:39Dhinesh Selvaraju: FDA Approves Narsoplimab (Yartemlea) as 1st Treatment for TA-TMA in Adults and Children
-
Apr 6, 2026, 16:38Linda Vorberg: A Detailed Analysis on The Usefulness of CT for DL-Based Stroke Lesion Segmentation
-
Apr 6, 2026, 16:37Colleen Hearn: Telestroke Helps Resource-Limited Facilities Gain Access to Unavailable Expertise
-
Apr 6, 2026, 16:37Nicolas Hubacz: AI Maps Neuroplasticity in Stroke Recovery – How the Brain Adapts After Injury
-
Apr 6, 2026, 16:36Cristina de Diego Alonso: Movement Is Not Just an Exercise, It Is The Rhythm of Daily Life
-
Apr 6, 2026, 16:35Charles Okyere Boadu: What Is The Most Likely Cause of Persistent Thrombocytopenia Despite Transfusion?
-
Apr 6, 2026, 16:34Tumor Mutations and VTE Risk – New Insights from a 12,500-Patient Cancer Study – JTH
-
Apr 6, 2026, 16:31Wolfgang Miesbach: New Real-World Data Reveal Ongoing Burden in Moderate-to-Severe Haemophilia A
-
Apr 6, 2026, 16:26Heghine Khachatryan։ Targeting High Risk Antiphospholipid Syndrome in Pregnancy with Hydroxychloroquine